Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Shivatra Talchai,

Medical Innovative Technology, Singapore

Title: Expansion of High Quality Mesenchymal Stem Cells On Xeno Free Cell Revtm Msc Exhq For Therapeutic Applications

Biography

Biography: Shivatra Talchai,

Abstract

Multipotent mesenchymal stem cells (MSCs) that have self-renewal properties and can differentiate into adipocytes, osteoblasts, chondrocytes and others. MSCs have been found to have immunomodulatory effects. Thus, MSCs represent an ideal source of stem cells for tissue engineering applications.

To ensure their quality, biocompatibility and consistency for clinical applications, it is essential for MSCs cultured ex vivo to retain of their self-renewal and differentiation capacities. Traditionally, fetal bovine serum (FBS), dubbed standard media (STD), is used as a supplement to support cells in in vitro culture. However, this is disadvantageous as FBS is posing clinical risks such as viral or prion contamination and immune rejection, as well as affecting the differentiation potential of MSCs. To produce high quality MSCs for clinical use, sera- and animal-free media are being developed. We therefore formulated a human platelet lysate-based, serum-free media, MSC ExHQ Cell RevTM media that can be used to expand MSCs while retaining their multipotent differentiation potentials. Here, we compare the properties of MSCs cultured in standard media (STD) versus in MSC ExHQ Cell RevTM media. We found that standard media leads to overexpression of MSC negative marker, CD19 while ExHQ media does not. Therefore, we suggest that MSC ExHQ Cell RevTM media is more appropriate media for high quality MSCs as well as for later clinical applications.